Effects of antiglaucoma drugs GLC756, a novel dopamine D2 agonist and D1 antagonist, and timolol on endotoxin-induced TNF-alpha release in serum of rats

European Journal of Ophthalmology

Volumn 16, Issue 3, 2006, Pages 401-406

  Laengle, Ulrich W ^a,b   Markstein, R ^a   Schneider, V ^a   Roman, D ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b MUT 2881133 ^*  (Switzerland)

Author keywords

Betamethasone; D1 antagonist; D2 agonist; Endotoxin; Glaucoma medication; GLC756; Rat; Serum; Timolol; TNF

Indexed keywords

1,2,3,4,4A,5,10,10A OCTAHYDRO 6 HYDROXY 1 METHYL 3 [(2 PYRIDYLTHIO)METHYL]BENZO[G]QUINOLINE; ANTIGLAUCOMA AGENT; BETAMETHASONE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ENDOTOXIN; EYE DROPS; GLC756; LIPOPOLYSACCHARIDE; SODIUM CHLORIDE; TIMOLOL; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; GLAUCOMA; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA; SALMONELLA TYPHIMURIUM; STATISTICAL SIGNIFICANCE;

EID: 33745908857     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210601600307     Document Type: Article

References (37)

1. Schuman JS. Short- and long-term safety of glaucoma drugs. Expert Opin Drug Saf 2002; 1:181-94.
2. Pruente C, Flammer J. The novel dopamine D1 antagonist and D2 agonist, SDZ GLC 756, lowers intraocular pressure in healthy human volunteers and in patients with glaucoma. Ophthalmology 1995; 102: 1291-7.
3. Prünte C, Flammer J, Markstein R, Rudin M. Quantification of optic nerve blood flow using MR-imaging. Invest Ophthalmol Vis Sci 1995; 36: 247-51.
4. Chiou GC, Chen YJ. Effects of dopamine agonist, bromocriptine, and some dopamine antagonists on ocular blood flow. J Ocul Pharmacol 1992; 8: 285-94.
5. Markstein R, Gull P, Rudeberg C, et al. SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors. J Neural Transm 1996; 103: 17-30.
6. Prunte C, Nuttli I, Markstein R. Topical SDZ GLC-756, a novel dopamine D-1 antagonist and D-2 agonist, lowers intraocular pressure in conscious rabbits. Jpn J Ophthalmol 1996; 40: 167-73.
7. Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology 1989; 96: 327-35.
8. Ariturk N, Oge I, Baris S, Erkan D, Sullu Y, Koc F. The effects of antiglaucomatous agents on conjunctiva used for various durations. Int Ophthalmol 1997; 20: 57-62.
9. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol 1994; 112: 1437-45.
10. Lark KK, Pasha AS, Yan X, Edward DP. The effect of latanoprost and brimonidine on rabbit subconjunctival fibroblasts. J Glaucoma 1999; 8: 72-6.
11. Maumenee AE. External filtering operations for glaucoma: the mechanism of function and failure. Trans Am Ophthalmol Soc 1960; 58: 319-28.
12. Flaxel JT, Swan KC. Limbal wound healing after cataract extraction. Arch Ophthalmol 1969; 81: 653-9.
13. Miller MH, Grierson I, Unger WI, Hitchings RA. Wound healing in an animal model of glaucoma fistulizing surgery in the rabbit. Ophthalmic Surg 1989; 20: 350-7.
14. Addicks EM, Quigley HA, Greene WR, Robin AL. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol 1983; 101: 795-8.
15. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci 1995; 36: 774-86.
16. Yan X, Tezel G, Wax MB, Edward DP. Matrix metalloproteinases and tumor necrosis factor alpha in glaucomatous optic nerve head. Arch Ophthalmol 2000; 118: 666-73.
17. Tezel G, Wax MB. Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J Neurosci 2000; 20: 8693-700.
18. Meli R, Raso GM, Gualillo O, Pacillo M, di Carlo R. Prolactin modulation of nitric oxide and TNF-alpha production by peripheral neutrophils in rats. Life Sci 1997; 61:1395-403.
19. Rosenbaum JT, McDevitt HO, Guss RB, Egbert PR. Endotoxin-induced uveitis in rats as a model for human disease. Nature 1980; 286: 611-3.
20. Feghali CA, Wright TM. Cytokines in acute and chronic inflammation. Frontiers Biosci 1997; 2: 12-6.
21. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 2006; 16: 38-52.
22. Perretti M, Duncan GS, Flower RJ, Peers SH. Serum corticosterone, interleukin-1 and tumour necrosis factor in rat experimental endotoxemia: comparison between Lewis and Wistar strains. Br J Pharmacol 1993; 110: 868-74.
23. De Vos AF, Hoekzema R, Kijlstra A. Cytokines and uveitis, a review. Curr Eye Res 1992; 11: 581-97.
24. De Vos AF, Van Haren MA, Verhagen C, Hoekzema R, Kijlstra A. Systemic anti-tumor necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat. Exp Eye Res 1995; 61: 667-75.
25. Fong Y, Lowry SF. Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin Immunol Immunopathol 1990; 55: 157-70.
26. Mastronardi CA, Yu WH, McCann S. Lipopolysaccharide-induced tumor necrosis factor-alpha release is controlled by the central nervous system. Neuroimmunomodulation 2001; 9: 148-56.
27. Hasko G, Szabo C, Merkel K, et al. Modulation of lipopolysaccharide- induced tumor necrosis factor-alpha and nitric oxide production by dopamine receptor agonists and antagonists in mice. Immunol Lett 1996; 49: 143-7.
28. Zhang H, De Jongh R, De Backer D, Cherkaoui S, Vray B, Vincent JL. Effects of alpha- and beta-adrenergic stimulation on hepatosplanchnic perfusion and oxygen extraction in endotoxic shock. Crit Care Med 2001; 29: 581-8.
29. Nakamura A, Johns EJ, Imaizumi A, Abe T, Kohsaka T. Regulation of tumour necrosis factor and interleukin-6 gene transcription by beta2-adrenoceptor in the rat astrocytes. J Neuroimmunol 1998; 88: 144-53.
30. Cloez-Tayarani I, Petit-Bertron AF, Venters HD, Cavaillon JM. Differential effect of serotonin on cytokine production in lipopolysaccharide- stimulated human peripheral blood mononuclear cells: involvement of 5-hydroxytryptamine2A receptors. Int Immunol 2003; 15: 233-40.
31. Längle UW, Markstein R, Court M, Roman D. Effects of antiglaucoma drugs timolol and GLC756, a novel dopamine D2 agonist and D1 antagonist, on endotoxin-induced-uveitis and -arthritis in rats. Exp Toxicol Pathol 2006 (in press).
32. BenEzra D, Wysenbeek YS, Cohen E. Increased intraocular pressure during treatment for chronic uveitis. Graefes Arch Clin Exp Ophthalmol 1997; 235: 200-3.
33. Grunblatt E, Mandel S, Youdim MB. Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP. Ann NY Acad Sci 2000; 899: 262-73.
34. Shin WH, Lee DY, Park KW, et al. Microglia expressing interleukin-13 undergo cell death and contribute to neuronal survival in vivo. Glia 2004; 46: 142-52.
35. Nakamura A, Johns EJ, Imaizumi A, Abe T, Kohsaka T. Regulation of tumour necrosis factor and interleukin-6 gene transcription by beta2-adrenoceptor in the rat astrocytes. J Neuroimmunol 1998; 88: 144-53.
36. Izeboud CA, Vermeulen RM, Zwart A, Voss HP, van Miert AS, Witkamp RF. Stereoselectivity at the beta2-adrenoceptor on macrophages is a major determinant of the anti-inflammatory effects of beta2-agonists. Naunyn Schmiedebergs Arch Pharmacol 2000; 362: 184-9.
37. Er H, Doganay S, Evereklioglu C, Cekmen M, Daglioglu MC, Isci N. Effects of L-NAME and timolol on aqueous IL-1beta, IL-6, IL-8, TNF-alpha and NO levels after Nd:YAG laser iridotomy in rabbits. Eur J Ophthalmol 2002; 12: 281-6.